Sugammadex To IMprove Bowel Function

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Colon and rectal surgery is associated with high cost, long length of stay, high postoperative surgical site infection rate, high incidence of postoperative nausea and vomiting, and a high rate of hospital readmission. Return of bowel function is of utmost importance in avoiding patient discomfort, morbidity, and mortality after colorectal surgery. All patient having colorectal surgery receive neuromuscular paralysis, which is reversed at the end of surgery with either glycopyrrolate and neostigmine, or sugammadex. Glycopyrrolate and neostigmine both affect bowel function. Sugammadex has no effect on bowel function. The purpose of this study is to determine if a strategy of neuromuscular reversal with sugammadex, instead of glycopyrrolate and neostigmine, may increase gastric emptying after surgery and lead to less postoperative complications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Having surgery in the South Operating Rooms at Oregon Health & Science University

• Surgery scheduled Monday through Friday

• Having colorectal surgery

• Planned general endotracheal anesthesia

Exclusion Criteria:

• Prisoners

• Pregnant women

• An inability to consent for surgery or anesthesia

• Allergy to a study drug

• Medical contraindication to neuromuscular blockade

• Stage 4 kidney disease or worse (glomerular filtration rate < 30 ml/min)

• Significant liver dysfunction (Aspartate transaminase or Alanine transaminase > twice the OHSU normal)

• Taking Toremifene